重组GDF11促进大鼠永久性缺血性亚急性卒中模型的恢复
研究在大鼠永久性大脑中动脉闭塞的亚急性卒中模型中,于伤后24至72小时给予单次或多次重组GDF11(0.1-4 mg/kg)或溶媒,并在6项由独立合同研究组织实施的盲法临床前研究中评估疗效。结果所有6项研究均显示rGDF11组感觉运动结局一致改善,皮层血管化和室管膜区放射状胶质细胞增加,血清CRP呈剂量依赖性降低,并鉴定出药效动力学和机制生物标志物。
要点
- 在大鼠永久性缺血性卒中模型中,伤后24至72小时给予rGDF11(0.1-4 mg/kg)可改善感觉运动功能。
- 6项由独立合同研究组织实施的盲法临床前研究均显示rGDF11组感觉运动结局一致改善。
- rGDF11组皮层血管化和室管膜区放射状胶质细胞增加,血清CRP呈剂量依赖性降低。
核心结论
- 全身递送的重组GDF11可增强血管新生、减轻炎症、促进神经发生并改善缺血性卒中大鼠模型伤后的感觉运动功能。
- 这些数据定义了用于缺血性卒中治疗开发的优化且临床可行的rGDF11给药方案,并鉴定出一组候选药效动力学和机制生物标志物以支持临床转化。
研究设计与样本
- 研究使用8至10周龄年轻成年雄性Sprague-Dawley大鼠,通过永久闭塞右侧大脑中动脉近端诱导局灶性脑梗死。
- 大鼠在伤后24至72小时接受单次或多次剂量的rGDF11(0.1-4 mg/kg)或溶媒。
- 在体外确认rGDF11活性,并在已建立的心脏肥厚和糖代谢小鼠体内模型中确认活性。
- 在6项临床前卒中研究中评估rGDF11疗效,这些研究由独立合同研究组织执行,所有研究动物和治疗组均设盲。
主要发现
- 所有6项研究均显示rGDF11组感觉运动结局一致改善。
- rGDF11治疗的大鼠皮层血管化和室管膜区放射状胶质细胞增加。
- 血清分析显示rGDF11引起CRP(C反应蛋白)剂量依赖性降低,并鉴定出新的药效动力学生物标志物及与rGDF11潜在作用机制相关的通路。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Stroke remains a leading cause of death and disability, underscoring the urgent need for treatments that enhance recovery. GDF11 (growth differentiation factor 11), a member of the TGF-β (transforming growth factor-β) superfamily, is a circulating protein involved in cellular development and tissue repair. GDF11 has gained attention for its potential regenerative properties in aging and disease contexts, making it a candidate for stroke recovery therapies. METHODS: The therapeutic benefits of rGDF11 (recombinant GDF11) were evaluated using a rat ischemic stroke model, in which focal cerebral infarcts were induced in 8- to 10-week-old young adult male Sprague-Dawley rats by permanently occluding the proximal right middle cerebral artery. Rats received single or multiple doses of rGDF11 (0.1-4 mg/kg) or vehicle from 24 to 72 hours post-injury. Sensorimotor functions were evaluated, and brain and serum samples were examined to determine the mechanisms of action and identify biomarkers, using immunofluorescence, target-specific ELISAs, and an aptamer-based proteomics platform. RESULTS: We confirmed rGDF11 activity in vitro and in established in vivo mouse models of cardiac hypertrophy and glucose metabolism and assessed the efficacy of rGDF11 treatment in 6 preclinical stroke studies using independent Contract Research Organizations, with all study animals and treatment groups blinded. All 6 studies revealed consistent improvement in sensorimotor outcomes with rGDF11. rGDF11-treated rats showed increased cortical vascularization and radial glia in the ventricular zone. Serum analysis revealed that rGDF11 caused dose-dependent decreases in CRP (C-reactive protein) and identified novel pharmacodynamic biomarkers and pathways associated with potential mechanisms of action of rGDF11. CONCLUSIONS: These results demonstrate that systemically delivered rGDF11 enhances neovascularization, reduces inflammation, promotes neurogenesis, and improves sensorimotor function post-injury in a rat model of ischemic stroke. More importantly, these data define an optimized and clinically feasible rGDF11 dosing regimen for therapeutic development in ischemic stroke and identify a panel of candidate pharmacodynamic and mechanistic biomarkers to support clinical translation.
引用
- Cohen OS, Sinha M, Wang Y, et al. Recombinant GDF11 Promotes Recovery in a Rat Permanent Ischemia Model of Subacute Stroke. Stroke. 2025. PMID: 39909827. doi:10.1161/STROKEAHA.124.049908
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。